Knockdown of REGγ inhibits the proliferation and migration and promotes the apoptosis of multiple myeloma cells by downregulating NF-κB signal pathway

Figures & data

Table 1. Clinical characteristics of MM patients and normal donors.

	MM (n = 28)	Normal donors (n = 16)
Gender (male/female)	15/13	10/6
Age	59 (18–86)	30 (10–45)
BMI	23.27 ± 1.78	22.77 ± 1.67
HGB (g/l)	80.32 ± 22.80	140.94 ± 13.37
ALB (g/l)	29.14 ± 5.30	39.86 ± 2.50
ISS stage
I	3	−
II	10	−
III	15	−
Monoclonal immunoglobulin type		−
IgA	10	−
IgD	2	−
IgG	9	−
IgM	1	−
Non-secretory	6	−

Note: BMI: body mass index; HGB: hemoglobin; ALB: albumin.

Figure 1. The proliferation and apoptosis of RPMI-8226 cells transfected with shRNA-REGγ-1 and shRNA-REGγ-2 (n = 3). (A) The proliferation rates of RPMI-8226 cells transfected with shRNA-REGγ-1 and shRNA-REGγ-2 by CCK8. (B) The apoptosis of RPMI-8226 cells transfected with shRNA-REGγ-1 and shRNA-REGγ-2 by flow cytometry. (C) The apoptosis rates of RPMI-8226 cells transfected with shRNA-REGγ-1 and shRNA-REGγ-2. *Represent significantly different at p < 0.05 when compared with the control (RPMI-8226 cells transfected with shN).

Figure 2. The migration of RPMI-8226 cells transfected with shRNA-REGγ-1 and shRNA-REGγ-2 by transwell assay (n = 3). (A) Microscopic observation of migrated RPMI-8226 cells. (B) The number of migrated cells. **Represent significantly different at p < 0.01 when compared with the control (RPMI-8226 cells transfected with shN).

Figure 3. The potential regulatory mechanisms of REGγ on RPMI-8226 cells. (A) The expression of p-p65, p65, IkBε and αREGγ in RPMI-8226 cells transfected with shRNA-REGγ-1 and shRNA-REGγ-2 by Western blot (n = 3). (B) The expression of IkBε in RPMI-8226 cells transfected with shRNA-REGγ-1 and shRNA-REGγ-2 by RT-PCR. (C) The degradation of IkBε (half-life period) in RPMI-8226 cells transfected with shRNA-REGγ-1. (D) The expression of REGγ, MMP2, Bcl-xL and XIAP in RPMI-8226 cells transfected with shRNA-REGγ-1 and shRNA-REGγ-2 by Western blot.